MACKENZIE US MID CAP OPPORTUNITIES CURRENCY NEUTRAL FUND

Quarterly Portfolio Disclosure

As at December 31, 2024

Summary of Investment Portfolio

PORTFOLIO ALLOCATION	% OF NAV
Equities	99.3
Cash and cash equivalents	4.4
Other assets (liabilities)	(3.7)
REGIONAL ALLOCATION	% OF NAV
United States	99.3
Cash and cash equivalents	4.4
Other assets (liabilities)	(3.7)
SECTOR ALLOCATION	% OF NAV
Health care	31.5
Information technology	26.5
Industrials	22.6
Financials	8.9
Real estate	5.2
	4.4
Cash and cash equivalents	
Cash and cash equivalents Consumer staples	3.8
·	3.8 0.8

TOP 25 POSITIONS	% OF NAV
Issuer	
CoStar Group Inc.	5.2
DexCom Inc.	5.1
Charles River Laboratories International Inc.	5.0
Akamai Technologies Inc.	5.0
Bio-Techne Corp.	4.8
Vontier Corp.	4.8
Cirrus Logic Inc.	4.8
SS&C Technologies Holdings Inc.	4.6
Cash and cash equivalents	4.4
HealthEquity Inc.	4.3
Hologic Inc.	4.2
MAXIMUS Inc.	4.1
ExlService Holdings Inc.	4.0
Exact Sciences Corp.	3.8
e.l.f. Beauty Inc.	3.8
Keysight Technologies Inc.	3.7
Jack Henry & Associates, Inc.	3.5
The Progressive Corp.	3.5
Wabtec Corp.	3.4
Tenable Holdings Inc.	2.9
Waters Corp.	2.8
Broadridge Financial Solutions Inc.	2.7
Equifax Inc.	2.0
Cognex Corp.	1.8
Dolby Laboratories Inc.	1.7
Top long positions as a percentage	
of total net asset value	95.9

The Fund held no short positions at the end of the period.

Total net asset value of the Fund

The investments and percentages may have changed since December 31, 2024, due to the ongoing portfolio transactions of the Fund. Quarterly updates of holdings are available within 60 days of the end of each quarter except for March 31, the Fund's fiscal year-end, when they are available within 90 days.



\$36.9 million